COMPANIES TO WATCH

  • Companies To Watch: Senti Bio

    Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.

  • Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.

  • Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.

  • Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.

WHERE ARE THEY NOW

  • Where Are They Now? Tarsus Pharmaceuticals

    Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.

  • Where Are They Now? Teva Pharmaceuticals

    Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.

  • Where Are They Now? Ironwood Pharmaceuticals

    Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.

ben-main

SPOTLIGHT

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.